Molecular mechanisms for enhanced DNA vaccine immunogenicity

References

• Rajcani J, Mosko T, Rezuchova I. Current developments in viral DNA vaccines: shall they solve the unsolved? Rev Med Virol. 2005;15(5):303–325.
   PubMed Web of Science ®Google Scholar
• Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res. 2008;42(1–3):219–232.
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239(1):62–84.
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–788.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–1468.
   PubMed Web of Science ®Google Scholar
• Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356(6365):152–154.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259(5102):1745–1749.
   PubMed Web of Science ®Google Scholar
• Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine. 1993;11(9):957–960.
   PubMed Web of Science ®Google Scholar
• Faurez F, Dory D, Le Moigne V, et al. Biosafety of DNA vaccines: new generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine. 2010;28(23):3888–3895.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740–745.
   PubMed Web of Science ®Google Scholar
• Rottembourg D, Filippi CM, Bresson D, et al. Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection. J Immunol. 2010;184(12):7100–7107.
   PubMed Web of Science ®Google Scholar
• Babiuk S, Mookherjee N, Pontarollo R, et al. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology. 2004;113(1):114–120.
   PubMed Web of Science ®Google Scholar
• Tudor D, Dubuquoy C, Gaboriau V, et al. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine. 2005;23(10):1258–1264.
   PubMed Web of Science ®Google Scholar
• Gao P, Ascano M, Wu Y, et al. Cyclic [G(2ʹ,5ʹ)pA(3ʹ,5ʹ)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell. 2013;153(5):1094–1107.
   PubMed Web of Science ®Google Scholar
• Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339(6121):786–791.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yeruva L, Marinov A, et al. The DNA sensor, cyclic GMP-AMP synthase, is essential for induction of IFN-beta during Chlamydia trachomatis infection. J Immunol. 2014;193(5):2394–2404.
   PubMed Web of Science ®Google Scholar
• Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 2007;448(7152):501–505.
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Kawagoe T, Koyama S, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature. 2008;451(7179):725–729.
   PubMed Web of Science ®Google Scholar
• Fernandes-Alnemri T, Yu JW, Juliana C, et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol. 2010;11(5):385–393.
   PubMed Web of Science ®Google Scholar
• Schroder K, Muruve DA, Tschopp J. Innate immunity: cytoplasmic DNA sensing by the AIM2 inflammasome. Curr Biol. 2009;19(6):R262–R265.
   PubMed Web of Science ®Google Scholar
• Suschak JJ, Wang S, Fitzgerald KA, et al. Identification of Aim2 as a sensor for DNA vaccines. J Immunol. 2015;194(2):630–636.
   PubMed Web of Science ®Google Scholar
• Sugimoto N, Mitoma H, Kim T, et al. Helicase proteins DHX29 and RIG-I cosense cytosolic nucleic acids in the human airway system. Proc Natl Acad Sci U S A. 2014;111(21):7747–7752.
   PubMed Web of Science ®Google Scholar
• Ferguson BJ, Mansur DS, Peters NE, et al. DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. Elife. 2012;1:e00047.
   PubMed Web of Science ®Google Scholar
• Jakobsen MR, Paludan SR. IFI16: at the interphase between innate DNA sensing and genome regulation. Cytokine Growth Factor Rev. 2014;25(6):649–655.
   PubMed Web of Science ®Google Scholar
• Kondo T, Kobayashi J, Saitoh T, et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A. 2013;110(8):2969–2974.
   PubMed Web of Science ®Google Scholar
• Parvatiyar K, Zhang Z, Teles RM, et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol. 2012;13(12):1155–1161.
   PubMed Web of Science ®Google Scholar
• Unterholzner L, Keating SE, Baran M, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010;11(11):997–1004.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yuan B, Bao M, et al. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol. 2011;12(10):959–965.
   PubMed Web of Science ®Google Scholar
• Racz R, Li X, Patel M, et al. DNAVaxDB: the first web-based DNA vaccine database and its data analysis. BMC Bioinformatics. 2014;15(Suppl 4):S2.
   PubMed Web of Science ®Google Scholar
• Uchijima M, Yoshida A, Nagata T, et al. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J Immunol. 1998;161(10):5594–5599.
   PubMed Web of Science ®Google Scholar
• Trollet C, Pereira Y, Burgain A, et al. Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer. Infect Immun. 2009;77(5):2221–2229.
   PubMed Web of Science ®Google Scholar
• Li K, Gao L, Gao H, et al. Codon optimization and woodchuck hepatitis virus posttranscriptional regulatory element enhance the immune responses of DNA vaccines against infectious bursal disease virus in chickens. Virus Res. 2013;175(2):120–127.
   PubMed Web of Science ®Google Scholar
• Seo JY, Chung HJ, Kim TJ. Codon-optimized expression of fish iridovirus capsid protein in yeast and its application as an oral vaccine candidate. J Fish Dis. 2013;36(9):763–768.
   PubMed Web of Science ®Google Scholar
• Spatz SJ, Volkening JD, Mullis R, et al. Expression of chicken parvovirus VP2 in chicken embryo fibroblasts requires codon optimization for production of naked DNA and vectored meleagrid herpesvirus type 1 vaccines. Virus Genes. 2013;47(2):259–267.
   PubMed Web of Science ®Google Scholar
• Williams JA. Improving DNA vaccine performance through vector design. Curr Gene Ther. 2014;14(3):170–189.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Lu F, Dai Y, et al. Synergistic enhancement of immunogenicity and protection in mice against Schistosoma japonicum with codon optimization and electroporation delivery of SjTPI DNA vaccines. Vaccine. 2010;28(32):5347–5355.
   PubMed Web of Science ®Google Scholar
• Liu X, Deng R, Wang J, et al. COStar: a D-star Lite-based dynamic search algorithm for codon optimization. J Theor Biol. 2014;344:19–30.
   PubMed Web of Science ®Google Scholar
• Jacobs TM, Yumerefendi H, Kuhlman B, et al. SwiftLib: rapid degenerate-codon-library optimization through dynamic programming. Nucleic Acids Res. 2015;43(5):e34.
   Web of Science ®Google Scholar
• Dobano C, Sedegah M, Rogers WO, et al. Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity. Exp Parasitol. 2009;122(2):112–123.
   PubMed Web of Science ®Google Scholar
• Varaldo PB, Miyaji EN, Vilar MM, et al. Mycobacterial codon optimization of the gene encoding the Sm14 antigen of Schistosoma mansoni in recombinant Mycobacterium bovis Bacille Calmette-Guerin enhances protein expression but not protection against cercarial challenge in mice. FEMS Immunol Med Microbiol. 2006;48(1):132–139.
   PubMedGoogle Scholar
• Mauro VP, Chappell SA. A critical analysis of codon optimization in human therapeutics. Trends Mol Med. 2014;20(11):604–613.
   PubMed Web of Science ®Google Scholar
• Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A. 1993;90(10):4455–4459.
   PubMed Web of Science ®Google Scholar
• Manthorpe M, Cornefert-Jensen F, Hartikka J, et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther. 1993;4(4):419–431.
   PubMed Web of Science ®Google Scholar
• Wang S, Farfan-Arribas DJ, Shen S, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006;24(21):4531–4540.
   PubMed Web of Science ®Google Scholar
• Vanniasinkam T, Reddy ST, Ertl HC. DNA immunization using a non-viral promoter. Virology. 2006;344(2):412–420.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wang F, Zhang Y, et al. Down-regulation of Prdx6 contributes to DNA vaccine induced vitiligo in mice. Mol Biosyst. 2011;7(3):809–816.
   PubMed Web of Science ®Google Scholar
• Luke JM, Vincent JM, Du SX, et al. Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Ther. 2011;18(4):334–343.
   PubMed Web of Science ®Google Scholar
• Jechlinger W, Azimpour Tabrizi C, Lubitz W, et al. Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J Mol Microbiol Biotechnol. 2004;8(4):222–231.
   PubMed Web of Science ®Google Scholar
• Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors. Nat Biotechnol. 2010;28(12):1287–1289.
   PubMed Web of Science ®Google Scholar
• Osborn MJ, McElmurry RT, Lees CJ, et al. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of alpha-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther. 2011;19(3):450–460.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Wu J, Xu Z, et al. Minicircle-oriP-IFNgamma: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma. PLoS One. 2011;6(5):e19407.
   PubMed Web of Science ®Google Scholar
• Dietz WM, Skinner NE, Hamilton SE, et al. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther. 2013;21(8):1526–1535.
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang F, Kay MA. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. Mol Ther. 2013;21(5):954–963.
   PubMed Web of Science ®Google Scholar
• Wang Q, Jiang W, Chen Y, et al. In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses. J Virol. 2014;88(4):1924–1934.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–496.
   PubMed Web of Science ®Google Scholar
• Marichal T, Ohata K, Bedoret D, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011;17(8):996–1002.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, DeWitt CM, Chastain M, et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine. 1999;18(1–2):18–28.
   PubMed Web of Science ®Google Scholar
• Khosroshahi KH, Ghaffarifar F, Sharifi Z, et al. Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii. Parasitol Res. 2012;111(1):403–411.
   PubMed Web of Science ®Google Scholar
• Cristillo AD, Ferrari MG, Hudacik L, et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol. 2011;92(Pt 1):128–140.
   PubMed Web of Science ®Google Scholar
• Karkada M, Weir GM, Quinton T, et al. A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. Vaccine. 2010;28(38):6176–6182.
   PubMed Web of Science ®Google Scholar
• Liu J, Wu J, Wang B, et al. Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection. J Med Virol. 2014;86(5):886–894.
   PubMed Web of Science ®Google Scholar
• Ma J, Wang H, Zheng X, et al. CpG/Poly (I:C) mixed adjuvant priming enhances the immunogenicity of a DNA vaccine against eastern equine encephalitis virus in mice. Int Immunopharmacol. 2014;19(1):74–80.
   PubMed Web of Science ®Google Scholar
• Oldenburg M, Kruger A, Ferstl R, et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science. 2012;337(6098):1111–1115.
   PubMed Web of Science ®Google Scholar
• Hansen J, Lindenstrom T, Lindberg-Levin J, et al. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice. Cancer Immunol Immunother. 2012;61(6):893–903.
   PubMed Web of Science ®Google Scholar
• Sajadian A, Tabarraei A, Soleimanjahi H, et al. Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol. 2014;159(8):1951–1960.
   PubMed Web of Science ®Google Scholar
• Jiang M, Yao J, Feng G. Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa infection. PLoS One. 2014;9(5):e96609.
   PubMed Web of Science ®Google Scholar
• Lu J, Jiang S, Ye S, et al. CpG oligodeoxynucleotide ligand potentiates the activity of the pVAX1-Sj26GST. Biomed Rep. 2013;1(4):609–613.
   PubMedGoogle Scholar
• Yu Y, Ma Y, Wh X, et al. Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines. Med Microbiol Immunol. 2015;204(4):481–491.
   Web of Science ®Google Scholar
• Luke JM, Simon GG, Soderholm J, et al. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol. 2011;85(3):1370–1383.
   PubMed Web of Science ®Google Scholar
• Martinez-Gil L, Goff PH, Hai R, et al. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol. 2013;87(3):1290–1300.
   PubMed Web of Science ®Google Scholar
• Imanishi T, Ishihara C, Badr Mel S, et al. Nucleic acid sensing by T cells initiates Th2 cell differentiation. Nat Commun. 2014;5:3566.
   PubMed Web of Science ®Google Scholar
• Lladser A, Mougiakakos D, Tufvesson H, et al. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther. 2011;19(3):594–601.
   PubMed Web of Science ®Google Scholar
• Geissler M, Gesien A, Tokushige K, et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 1997;158(3):1231–1237.
   PubMed Web of Science ®Google Scholar
• Nobiron I, Thompson I, Brownlie J, et al. Co-administration of IL-2 enhances antigen-specific immune responses following vaccination with DNA encoding the glycoprotein E2 of bovine viral diarrhoea virus. Vet Microbiol. 2000;76(2):129–142.
   PubMed Web of Science ®Google Scholar
• Hu H, Tao L, Wang Y, et al. Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice. Biotechnol Lett. 2009;31(11):1685–1693.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Nottingham LK, Wilson DM, et al. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine. 1998;16(19):1828–1835.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Simbiri KA, Sin JI, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res. 1999;19(1):77–84.
   PubMed Web of Science ®Google Scholar
• Moore AC, Kong WP, Chakrabarti BK, et al. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol. 2002;76(1):243–250.
   PubMed Web of Science ®Google Scholar
• Henke A, Rohland N, Zell R, et al. Co-expression of interleukin-2 by a bicistronic plasmid increases the efficacy of DNA immunization to prevent influenza virus infections. Intervirology. 2006;49(4):249–252.
   PubMedGoogle Scholar
• Barouch DH, Santra S, Steenbeke TD, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol. 1998;161(4):1875–1882.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Truitt DM, Letvin NL. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine. 2004;22(23–24):3092–3097.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000;290(5491):486–492.
   PubMed Web of Science ®Google Scholar
• Zhu C, Yu M, Gao S, et al. [Protective immune responses induced by intranasal immunization with Mycoplasma pneumoniae P1C-IL-2 fusion DNA vaccine in mice]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013;29(6):585–588.
   PubMedGoogle Scholar
• Qin Y, Tian H, Wang G, et al. A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice. Biomed Res Int. 2013;2013:136492.
   PubMedGoogle Scholar
• Bhaumik S, Basu R, Sen S, et al. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine. 2009;27(9):1306–1316.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Hoyt T, Yang X, et al. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun. 2008;76(10):4564–4573.
   PubMed Web of Science ®Google Scholar
• Yang SH, Lee CG, Park SH, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 2006;13(14):1110–1117.
   PubMed Web of Science ®Google Scholar
• Naderi M, Saeedi A, Moradi A, et al. Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virol Sin. 2013;28(3):167–173.
   PubMedGoogle Scholar
• Zhao HG, Huang FY, Guo JL, et al. Evaluation on the immune response induced by DNA vaccine encoding MIC8 co-immunized with IL-12 genetic adjuvant against Toxoplasma gondii infection. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2013;31(4):284–289.
   PubMedGoogle Scholar
• Li J, Valentin A, Kulkarni V, et al. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine. 2013;31(36):3747–3755.
   PubMed Web of Science ®Google Scholar
• Kalams SA, Parker SD, Elizaga M, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis. 2013;208(5):818–829.
   PubMed Web of Science ®Google Scholar
• Yoon HA, Aleyas AG, George JA, et al. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol Immunol. 2006;50(2):83–92.
   PubMed Web of Science ®Google Scholar
• Lu H, Xu XF, Gao N, et al. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice. Mol Immunol. 2013;54(2):109–114.
   PubMed Web of Science ®Google Scholar
• Lena P, Villinger F, Giavedoni L, et al. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine. 2002;20(Suppl 4):A69–A79.
   PubMed Web of Science ®Google Scholar
• O’Neill E, Martinez I, Villinger F, et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol. 2002;31(4–5):217–227.
   PubMed Web of Science ®Google Scholar
• Chen H, Gao N, Wu J, et al. Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice. Immunol Lett. 2014;162(1 Pt A):140–148.
   PubMed Web of Science ®Google Scholar
• Hellerstein M, Xu Y, Marino T, et al. Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine. Hum Vaccin Immunother. 2012;8(11):1654–1658.
   PubMed Web of Science ®Google Scholar
• Bergamaschi C, Kulkarni V, Rosati M, et al. Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells. Gene Ther. 2015;22(1):76–86.
   PubMed Web of Science ®Google Scholar
• Chen J, Li ZY, Huang SY, et al. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice. BMC Infect Dis. 2014;14:487.
   PubMed Web of Science ®Google Scholar
• Li ZY, Chen J, Petersen E, et al. Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice. Vaccine. 2014;32(25):3058–3065.
   PubMed Web of Science ®Google Scholar
• Su B, Wang J, Zhao G, et al. Sequential administration of cytokine genes to enhance cellular immune responses and CD4 (+) T memory cells during DNA vaccination. Hum Vaccin Immunother. 2012;8(11):1659–1667.
   PubMed Web of Science ®Google Scholar
• Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189–209.
   PubMed Web of Science ®Google Scholar
• Chu D, Moroda M, Piao LX, et al. CTL induction by DNA vaccine with Toxoplasma gondii-HSP70 gene. Parasitol Int. 2014;63(2):408–416.
   PubMed Web of Science ®Google Scholar
• Zhou J, Cheung AK, Tan Z, et al. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest. 2013;123(6):2629–2642.
   PubMed Web of Science ®Google Scholar
• Liniger M, Summerfield A, Ruggli N. MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens. PLoS One. 2012;7(12):e49952.
   PubMed Web of Science ®Google Scholar
• Castaldello A, Sgarbanti M, Marsili G, et al. Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination. J Cell Physiol. 2010;224(3):702–709.
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Tingey C, Mahadevan L, et al. Co-administration of molecular adjuvants expressing NF-kappa B subunit p65/RelA or type-1 transactivator T-bet enhance antigen specific DNA vaccine-induced immunity. Vaccines. 2014;2(2):196–215.
   Google Scholar
• Chen LP, Zhang RB, Hu D, et al. [Immune regulation of T-bet adjuvant on Ag85B DNA vaccine against Mycobacterium tuberculosis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012;28(7):680–683.
   PubMedGoogle Scholar
• Hu D, Wu J, Zhang R, et al. T-bet acts as a powerful adjuvant in Ag85B DNAbased vaccination against tuberculosis. Mol Med Rep. 2012;6(1):139–144.
   PubMed Web of Science ®Google Scholar
• Peng J, Zhao Y, Mai J, et al. Short noncoding DNA fragment improve efficiencies of in vivo electroporation-mediated gene transfer. J Gene Med. 2012;14(9–10):563–569.
   PubMed Web of Science ®Google Scholar
• Peng J, Shi S, Yang Z, et al. Short noncoding DNA fragments improve the immune potency of electroporation-mediated HBV DNA vaccination. Gene Ther. 2014;21(7):703–708.
   PubMed Web of Science ®Google Scholar
• Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 2010;28(11):570–579.
   PubMed Web of Science ®Google Scholar
• Geiben-Lynn R, Frimpong-Boateng K, Letvin NL. Modulation of plasmid DNA vaccine antigen clearance by caspase 12 RNA interference potentiates vaccination. Clin Vaccine Immunol. 2011;18(4):533–538.
   PubMed Web of Science ®Google Scholar
• Wang ST, Chang CC, Yen MC, et al. RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency. Gene Ther. 2011;18(4):372–383.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kang TH, Noh KH, et al. Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Clin Exp Immunol. 2011;165(2):180–189.
   PubMed Web of Science ®Google Scholar
• Jiang W. Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice. Vaccine. 2012;30(4):758–766.
   PubMed Web of Science ®Google Scholar
• Pradhan P, Qin H, Leleux JA, et al. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials. 2014;35(21):5491–5504.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Barve M, Orr D, et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver. Oncology. 2014;87(1):21–29.
   PubMed Web of Science ®Google Scholar
• Almeida RR, Raposo RA, Coirada FC, et al. Modulating APOBEC expression enhances DNA vaccine immunogenicity. Immunol Cell Biol. 2015;93(10):868–876.
   PubMed Web of Science ®Google Scholar
• Chen YZ, Ruan GX, Yao XL, et al. Co-transfection gene delivery of dendritic cells induced effective lymph node targeting and anti-tumor vaccination. Pharm Res. 2013;30(6):1502–1512.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–277.
   PubMed Web of Science ®Google Scholar
• Liu H, Moynihan KD, Zheng Y, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–522.
   PubMed Web of Science ®Google Scholar
• Toke ER, Lorincz O, Csiszovszki Z, et al. Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes. Gene Ther. 2014;21(6):566–574.
   PubMed Web of Science ®Google Scholar
• Ye C, Choi JG, Abraham S, et al. Targeting DNA vaccines to myeloid cells using a small peptide. Eur J Immunol. 2015;45(1):82–88.
   PubMed Web of Science ®Google Scholar
• Cao J, Jin Y, Li W, et al. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice. BMC Immunol. 2013;14:39.
   PubMed Web of Science ®Google Scholar
• Fossum E, Grodeland G, Terhorst D, et al. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8 T-cell responses against influenza virus. Eur J Immunol. 2015;45(2):624–635.
   PubMed Web of Science ®Google Scholar
• Moulin V, Morgan ME, Eleveld-Trancikova D, et al. Targeting dendritic cells with antigen via dendritic cell-associated promoters. Cancer Gene Ther. 2012;19(5):303–311.
   PubMed Web of Science ®Google Scholar
• Corbett AJ, Caminschi I, McKenzie BS, et al. Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional “danger”. Eur J Immunol. 2005;35(10):2815–2825.
   PubMed Web of Science ®Google Scholar
• Daftarian P, Kaifer AE, Li W, et al. Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. Cancer Res. 2011;71(24):7452–7462.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Fujihashi K, Oma K, et al. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun. 2011;79(7):2819–2828.
   PubMed Web of Science ®Google Scholar
• Lahoud MH, Ahmet F, Kitsoulis S, et al. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J Immunol. 2011;187(2):842–850.
   PubMed Web of Science ®Google Scholar
• Njongmeta LM, Bray J, Davies CJ, et al. CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4(+) T cell responses following DNA vaccination of outbred animals. Vaccine. 2012;30(9):1624–1635.
   PubMed Web of Science ®Google Scholar
• Freitas EB, Henriques AM, Fevereiro M, et al. Enhancement of DNA vaccine efficacy by intracellular targeting strategies. Methods Mol Biol. 2014;1143:33–59.
   PubMedGoogle Scholar
• Godinho RM, Matassoli FL, Lucas CG, et al. Regulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response. PLoS One. 2014;9(6):e99887.
   PubMed Web of Science ®Google Scholar
• Hu D, Wu J, Zhang R, et al. Autophagy-targeted vaccine of LC3-LpqH DNA and its protective immunity in a murine model of tuberculosis. Vaccine. 2014;32(20):2308–2314.
   PubMed Web of Science ®Google Scholar
• Meerak J, Wanichwecharungruang SP, Palaga T. Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system. Vaccine. 2013;31(5):784–790.
   PubMed Web of Science ®Google Scholar
• Saiga H, Nieuwenhuizen N, Gengenbacher M, et al. The recombinant BCG DeltaureC::hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation. J Infect Dis. 2015;211(11):1831–1841.
   PubMed Web of Science ®Google Scholar
• Fu X, Tao L, Zhang X. A short polypeptide from the herpes simplex virus type 2 ICP10 gene can induce antigen aggregation and autophagosomal degradation for enhanced immune presentation. Hum Gene Ther. 2010;21(12):1687–1696.
   PubMed Web of Science ®Google Scholar
• Capitani M, Saade F, Havas KM, et al. Plasmids encoding protein aggregation domains act as molecular adjuvants for DNA vaccines. Curr Gene Ther. 2014;14(3):161–169.
   PubMedGoogle Scholar
• Smahel M, Polakova I, Duskova M, et al. The effect of helper epitopes and cellular localization of an antigen on the outcome of gene gun DNA immunization. Gene Ther. 2014;21(2):225–232.
   PubMed Web of Science ®Google Scholar
• Romani N, Flacher V, Tripp CH, et al. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol. 2012;351:113–138.
   PubMed Web of Science ®Google Scholar
• Wang Y, Guo Y, Wang X, et al. Serum amyloid P component facilitates DNA clearance and inhibits plasmid transfection: implications for human DNA vaccine. Gene Ther. 2012;19(1):70–77.
   Web of Science ®Google Scholar
• Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011;12(8):786–795.
   PubMed Web of Science ®Google Scholar
• Trautmann L, Sekaly RP. Solving vaccine mysteries: a systems biology perspective. Nat Immunol. 2011;12(8):729–731.
   PubMed Web of Science ®Google Scholar
• Kennedy RB, Poland GA. The top five “game changers” in vaccinology: toward rational and directed vaccine development. OMICS. 2011;15(9):533–537.
   Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Kennedy RB, et al. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS. 2011;15(9):625–636.
   Web of Science ®Google Scholar
• Li S, Nakaya HI, Kazmin DA, et al. Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol. 2013;25(3):209–218.
   PubMed Web of Science ®Google Scholar
• Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011;6(8):e21225.
   PubMed Web of Science ®Google Scholar
• De Rosa SC, Thomas EP, Bui J, et al. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol. 2011;187(6):3391–3401.
   PubMed Web of Science ®Google Scholar
• Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One. 2010;5(9):e12873.
   PubMed Web of Science ®Google Scholar
• Koblin BA, Casapia M, Morgan C, et al. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS One. 2011;6(9):e24517.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011;11(12):916–924.
   PubMed Web of Science ®Google Scholar
• Fournillier A, Frelin L, Jacquier E, et al. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis. 2013;208(6):1008–1019.
   PubMed Web of Science ®Google Scholar
• Chuang I, Sedegah M, Cicatelli S, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One. 2013;8(2):e55571.
   PubMed Web of Science ®Google Scholar
• Cervantes-Villagrana AR, Hernandez-Pando R, Biragyn A, et al. Prime-boost BCG vaccination with DNA vaccines based in beta-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model. Vaccine. 2013;31(4):676–684.
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Qu BX, Fu M, et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Abeta42 DNA vaccine for Alzheimer disease. J Neuroimmunol. 2013;254(1–2):63–68.
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Dimitrova M, et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis. 2013;208(3):413–417.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Zephir K, Hu Z, et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis. 2013;208(3):418–422.
   PubMed Web of Science ®Google Scholar
• Lee SH, Danishmalik SN, Sin JI. DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother. 2015;11(8):1889–1900.
   PubMed Web of Science ®Google Scholar
• Broderick KE, Humeau LM. Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev Vaccines. 2015;14(2):195–204.
   PubMed Web of Science ®Google Scholar
• Shah MA, He N, Li Z, et al. Nanoparticles for DNA vaccine delivery. J Biomed Nanotechnol. 2014;10(9):2332–2349.
   PubMed Web of Science ®Google Scholar
• McCaffrey J, Donnelly RF, McCarthy HO. Microneedles: an innovative platform for gene delivery. Drug Deliv Transl Res. 2015;5(4):424–437.
   PubMed Web of Science ®Google Scholar
• Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014;2(6):159–182.
   PubMedGoogle Scholar
• Hooper JW, Moon JE, Paolino KM, et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect. 2014;20(Suppl 5):110–117.
   PubMed Web of Science ®Google Scholar
• Nilsson C, Hejdeman B, Godoy-Ramirez K, et al. HIV-DNA given with or without Intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA/MVA vaccinees: a phase I randomized trial. PLoS One. 2015;10(6):e0131748.
   PubMed Web of Science ®Google Scholar
• Borggren M, Nielsen J, Bragstad K, et al. Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans. Hum Vaccin Immunother. 2015;11(8):1983–1990.
   PubMed Web of Science ®Google Scholar
• Graham BS, Enama ME, Nason MC, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One. 2013;8(4):e59340.
   PubMed Web of Science ®Google Scholar
• Chen X, Fernando GJ, Crichton ML, et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release. 2011;152(3):349–355.
   PubMed Web of Science ®Google Scholar
• Pearson FE, McNeilly CL, Crichton ML, et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. Plos One. 2013;8(7):e67888.
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Oudshoorn M, Romeijn S, et al. Cationic submicron emulsions for pulmonary DNA immunization. J Control Release. 2004;100(1):145–155.
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Van Meijgaarden KE, Franken KL, et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine. 2004;22(13–14):1609–1615.
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Ottenhoff TH, Junginger HE, et al. Pulmonary DNA vaccination: concepts, possibilities and perspectives. J Control Release. 2005;107(1):1–29.
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Lin MY, Bal SM, et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine. 2009;27(30):4010–4017.
   PubMed Web of Science ®Google Scholar
• Mann JF, McKay PF, Arokiasamy S, et al. Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. J Control Release. 2013;170(3):452–459.
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Gillard GO, Bar L, et al. Airway CD8(+) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity. Mucosal Immunol. 2013;6(1):156–166.
   PubMed Web of Science ®Google Scholar
• Rajapaksa AE, Ho JJ, Qi A, et al. Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respir Res. 2014;15:60.
   PubMed Web of Science ®Google Scholar